ReviewOrthopaedic surgery2026
Inflammatory Pseudotumor After Total Hip Arthroplasty-An Increasingly Recognized Complication.
Review in Orthopaedic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Inflammatory pseudotumor (IP) is an increasingly recognized etiological factor in the failure of total hip arthroplasty (THA). It is a non-neoplastic, non-infectious mass encircling a hip prosthesis following arthroplasty and may appear as cystic, solid, or mixed tissue. Although initially associated with metal-on-metal (MoM) bearing surfaces, IP formation can also occur with other bearing types. Recognized risk factors include female sex, specific genetic predispositions, MoM bearings, large femoral head size, modular femoral stem designs, elevated metal ion levels, and wear debris from polyethylene components. IP contributes to THA failure through both mechanical and inflammatory mechanisms, often leading to pain, instability, or implant loosening. Diagnosis relies heavily on imaging modalities, including plain radiographs, ultrasound, CT, and MRI with metal artifact reduction sequences (MARS-MRI), which help delineate the extent and characteristics of IP lesions. A multimodal imaging approach is essential for accurate assessment and surgical planning. Management strategies are guided by clinical presentation and radiographic findings, such as IP size and anatomical location, ranging from close observation in asymptomatic cases to revision surgery in symptomatic or progressive disease. IP is therefore an important, imaging-detectable cause of THA failure, and awareness of its presentation and diagnostic features is critical for timely intervention and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.